Related Experiment Video

Updated: May 9, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Which oral anticoagulant for which atrial fibrillation patient: recent clinical trials and evidence-based choices

John A Cairns1

  • 1Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

The Canadian Journal of Cardiology
|August 13, 2013
PubMed

Insights

Novel oral anticoagulants (NOACs) offer easier management and comparable or superior stroke prevention compared to warfarin for atrial fibrillation patients. Guidelines now favor NOACs, but patient-specific factors guide the choice among dabigatran, rivaroxaban, and apixaban.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Oral anticoagulants are recommended for nonvalvular atrial fibrillation (NVAF) patients at risk of stroke.
  • Warfarin is effective but challenging to manage for patients and physicians.
  • Novel oral anticoagulants (NOACs) present an alternative with improved usability.

Purpose of the Study:

  • To compare the efficacy and safety of NOACs (dabigatran, rivaroxaban, apixaban) against warfarin for stroke prevention in NVAF.
  • To discuss the differences among NOACs regarding patient characteristics and clinical decision-making.
  • To provide guidance on selecting the most appropriate NOAC for individual NVAF patients.

Main Methods:

  • Review of current practice guidelines and clinical trial data comparing NOACs and warfarin.
  • Analysis of pharmacokinetic and pharmacodynamic characteristics of NOACs.
  • Discussion of patient-specific factors influencing NOAC selection.

Main Results:

  • NOACs are noninferior or superior to warfarin in preventing stroke and/or systemic embolism.
  • Major bleeding rates with NOACs are comparable to warfarin.
  • NOACs demonstrate significantly easier patient use and physician management compared to warfarin.

Conclusions:

  • Current guidelines generally recommend NOACs over warfarin for stroke prevention in NVAF, except in specific circumstances.
  • Differences in patient characteristics, side effects, dosing, and cost-effectiveness necessitate careful consideration when choosing among dabigatran, rivaroxaban, and apixaban.
  • Individualized patient assessment is crucial for optimal NOAC selection in NVAF management.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...